Please use this identifier to cite or link to this item: http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2188
Full metadata record
DC FieldValueLanguage
dc.contributor4495es_ES
dc.contributor243523es_ES
dc.contributor4494es_ES
dc.contributor.otherhttps://orcid.org/0000-0002-3403-9849-
dc.coverage.spatialGlobales_ES
dc.creatorAvalos Díaz, Esperanza del Refugio-
dc.creatorPérez Pérez, Elena-
dc.creatorRodríguez Rodríguez, Mayra-
dc.creatorPacheco Tovar, María Guadalupe-
dc.creatorHerrera Esparza, Rafael-
dc.date.accessioned2020-12-10T05:27:25Z-
dc.date.available2020-12-10T05:27:25Z-
dc.date.issued2016-06-01-
dc.identifierinfo:eu-repo/semantics/publishedVersiones_ES
dc.identifier.issn2049-9434es_ES
dc.identifier.issn2049-9442es_ES
dc.identifier.urihttp://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2188-
dc.identifier.urihttps://doi.org/10.48779/b3h3-wk28-
dc.description.abstractVitiligo is a chronic disease characterized by the dysfunction or destruction of melanocytes with secondary depigmentation. The aim of the present study was to determine the prevalence of vitiligo associated with autoimmune rheumatic diseases. The clinical records from a 10-year database of patients with rheumatic diseases and associated vitiligo was analysed, with one group of patients having autoimmune rheumatic disease and another non-autoimmune rheumatic disease. Available serum samples were used to assess the anti-melanocyte antibodies. A total of 5,251 individual clinical files were archived in the last 10 years, and these patients underwent multiple rheumatology consultations, with 0.3% of the group presenting with vitiligo. The prevalence of vitiligo in the autoimmune rheumatic disease group was 0.672%, which was mainly associated with lupus and arthritis. However, patients with more than one autoimmune disease had an increased relative risk to develop vitiligo, and anti-melanocyte antibodies were positive in 92% of these patients. By contrast, the prevalence was 0.082% in the group that lacked autoimmune rheumatic disease and had negative autoantibodies. In conclusion, the association between vitiligo and autoimmune rheumatic diseases was relatively low. However, the relative risk increased when there were other autoimmune comorbidities, such as thyroiditis or celiac disease. Therefore, the presence of multiple autoimmune syndromes should be suspected.es_ES
dc.language.isoenges_ES
dc.publisherSpandidos Publicationses_ES
dc.relationhttps://www.spandidos-publications.com/10.3892/br.2016.700/abstractes_ES
dc.relation.urigeneralPublices_ES
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Estados Unidos de América*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.sourceBiomedical Reports Vol. 5, No. 2, pp. 176-180es_ES
dc.subject.classificationMEDICINA Y CIENCIAS DE LA SALUD [3]es_ES
dc.subject.otherVitiligoes_ES
dc.subject.otherchronic diseasees_ES
dc.subject.otherdestruction of melanocyteses_ES
dc.titleAutoimmune vitiligo in rheumatic disease in the mestizo Mexican populationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
Appears in Collections:*Documentos Académicos*-- UA Medicina

Files in This Item:
File Description SizeFormat 
Autoimmune vitiligo in rheumatic disease.pdf883,74 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons